TY - JOUR
T1 - Phase II evaluation of pyrazofurin in patients with metastatic sarcoma
AU - Gralla, R. J.
AU - Sordillo, P. P.
AU - Magill, G. B.
PY - 1978/12/1
Y1 - 1978/12/1
N2 - Twenty-seven patients with metastatic sarcoma were treated with weekly doses of iv pyrazofurin. No patient experienced a major therapeutic response; dose-limiting toxic effects included mucositis and anemia not associated with hemorrhage. Although routine studies (haptoglobin, reticulocyte counts, lactic dehydrogenase, bilirubin, and Coombs' tests) did not reveal evidence of hemolysis, this possibility cannot be ruled out at this time. Preliminary studies by Dyke et al have indicated a decrease in survival of 51Cr-labeled rbcs in a pyrazofurin-treated patient when compared with a pretreatment study. Although all patients treated in the present trial had received prior chemotherapy, their general physical condition was good enough to allow outpatient management. With failure to achieve a partial remission in this number of patients, it can be concluded that pyrozofurin is likely to have a true major response rate of <15% (P=0.05)(9) and it would appear to have little therapeutic value in this schedule as a single agent in previously treated patients with advanced metastatic sarcoma.
AB - Twenty-seven patients with metastatic sarcoma were treated with weekly doses of iv pyrazofurin. No patient experienced a major therapeutic response; dose-limiting toxic effects included mucositis and anemia not associated with hemorrhage. Although routine studies (haptoglobin, reticulocyte counts, lactic dehydrogenase, bilirubin, and Coombs' tests) did not reveal evidence of hemolysis, this possibility cannot be ruled out at this time. Preliminary studies by Dyke et al have indicated a decrease in survival of 51Cr-labeled rbcs in a pyrazofurin-treated patient when compared with a pretreatment study. Although all patients treated in the present trial had received prior chemotherapy, their general physical condition was good enough to allow outpatient management. With failure to achieve a partial remission in this number of patients, it can be concluded that pyrozofurin is likely to have a true major response rate of <15% (P=0.05)(9) and it would appear to have little therapeutic value in this schedule as a single agent in previously treated patients with advanced metastatic sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=0018234269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018234269&partnerID=8YFLogxK
M3 - Article
C2 - 361228
AN - SCOPUS:0018234269
VL - 62
SP - 1573
EP - 1574
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 10
ER -